Citadel Advisors
HRMY icon

Citadel Advisors’s Harmony Biosciences HRMY Stock Holding History

Citadel Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.4M Buy
585,623
+165,213
+39% +$5.42M ﹤0.01% 2577
2025
Q4 		$15.7M Buy
420,410
+352,398
+518% +$11.6M ﹤0.01% 2644
2025
Q3 		$1.87M Buy
+68,012
New +$2.34M ﹤0.01% 6201
2025
Q2 		– Sell
-862,406
Closed -$27.7M – 13598
2025
Q1 		$28.6M Sell
862,406
-505,826
-37% -$18.1M 0.01% 1640
2024
Q4 		$47.1M Buy
1,368,232
+1,213,556
+785% +$41.7M 0.01% 1321
2024
Q3 		$6.19M Sell
154,676
-529,642
-77% -$18.6M ﹤0.01% 3612
2024
Q2 		$20.6M Buy
684,318
+102,698
+18% +$3.09M ﹤0.01% 1971
2024
Q1 		$19.5M Buy
581,620
+502,887
+639% +$16.1M ﹤0.01% 2094
2023
Q4 		$2.54M Sell
78,733
-163,347
-67% -$4.56M ﹤0.01% 4949
2023
Q3 		$7.93M Sell
242,080
-558,780
-70% -$19.4M ﹤0.01% 2979
2023
Q2 		$28.2M Buy
800,860
+269,053
+51% +$9.29M 0.01% 1542
2023
Q1 		$17.4M Buy
531,807
+395,854
+291% +$18M ﹤0.01% 2075
2022
Q4 		$7.49M Sell
135,953
-8,250
-6% -$454K ﹤0.01% 3228
2022
Q3 		$6.39M Buy
144,203
+70,740
+96% +$3.45M ﹤0.01% 3468
2022
Q2 		$3.58M Sell
73,463
-95,016
-56% -$4.28M ﹤0.01% 4435
2022
Q1 		$8.2M Buy
168,479
+78,048
+86% +$3.18M ﹤0.01% 3281
2021
Q4 		$3.86M Buy
90,431
+49,384
+120% +$1.97M ﹤0.01% 4831
2021
Q3 		$1.57M Sell
41,047
-3,724
-8% -$120K ﹤0.01% 6969
2021
Q2 		$1.26M Sell
44,771
-6,008
-12% -$180K ﹤0.01% 7732
2021
Q1 		$1.68M Buy
50,779
+23,196
+84% +$814K ﹤0.01% 6828
2020
Q4 		$997K Sell
27,583
-192,010
-87% -$7.75M ﹤0.01% 6797
2020
Q3 		$7.45M Buy
+219,593
New +$8.01M ﹤0.01% 2632

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Citadel Advisors's HRMY Position: Q1 2026 in Review

Citadel Advisors increased its Harmony Biosciences (HRMY) stake by 39% in Q1 2026, buying an estimated $5.42M and bringing the position to 585,623 shares worth $16.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2577.

Citadel Advisors first reported a position in HRMY in Q3 2020 and has held it in 22 quarters since. The position peaked at $47.1M in Q4 2024. 309 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • Citadel Advisors held 585,623 shares of Harmony Biosciences worth $16.4M as of Q1 2026.
  • Citadel Advisors bought 165,213 Harmony Biosciences shares in Q1 2026, an estimated $5.42M.
  • Harmony Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2577 holding.
  • Citadel Advisors first reported a position in Harmony Biosciences in Q3 2020 and has held it in 22 quarters since.
  • Citadel Advisors's Harmony Biosciences position peaked at $47.1M in Q4 2024.
  • 309 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.